Page last updated: 2024-11-13

copper bis(3,5-diisopropylsalicylate)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

copper bis(3,5-diisopropylsalicylate): copper is intricate part of molecule; not copper salt; RN given refers to cpd with specified locants for methylethyl moieties [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID110876794
MeSH IDM0097402

Synonyms (5)

Synonym
copper bis(3,5-diisopropylsalicylate)
copper, bis(3,5-diisopropylsalicylato)-
copper, bis(2-(hydroxy-kappao)-3,5-bis(1-methylethyl)benzoato-kappao)-
copper, bis(2-hydroxy-3,5-bis(1-methylethyl)benzoato-o(sup 1),o(sup 2))
mfcd00245080

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Analyses of dose-response curves suggest (i) CuDIPS preferentially inhibits BP mutagenesis; (ii) the antimutagenic activity of CuDIPS towards DMBA and the cytotoxicity of the copper complex are derived from the DIPS component of the chelate; (iii) the antimutagenic activity of CuDIPS towards BP requires both copper and DIPS; and (iv) DIPS and CuDIPS induced cytotoxicity is required for inhibition of mutagenesis."( Survey of cytotoxicities and antimutagenic and antitumor initiating activities of Cu(II)(3,5-diisopropylsalicylate)2 and its analogs in a keratinocyte-mediated mutation assay and the murine skin multistage carcinogenesis model.
Colby, AB; Reiners, JJ, 1988
)
0.27
" Injection of the same dosage of the ligand 3,5-diisopropyl salicylate has no effect on streptozotocin-induced hyperglycemia."( The antioxidant activity of copper(II) (3,5-diisopropyl salicylate)4 and its protective effect against streptozotocin-induced diabetes mellitus in rats.
Abdul-Ghani, AS; Abdul-Ghani, R; Abu-Hijleh, AL; Husein, R; Metani, M; Qazzaz, M, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (50.88)18.7374
1990's20 (35.09)18.2507
2000's6 (10.53)29.6817
2010's2 (3.51)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]